Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.

J Autoimmun. 1999 Nov;13(3):347-55. Unique Identifier : AIDSLINE MED/20019756
Petrovas C; Vlachoyiannopoulos PG; Kordossis T; Moutsopoulos HM; Department of Pathophysiology, Medical School, National; University of Athens, Athens, Greece.


Abstract: Increased prevalence of anti-phospholipid antibodies (aPL) and increased levels of lipid peroxidation have been described in patients with HIV infection. To assess the binding specificity and avidity of aPL antibodies in HIV infection, sera from 44 HIV-1 infected patients were evaluated for antibodies to cardiolipin (aCL), phosphatidyl serine (aPS), phosphatidyl inositol (aPI) and phosphatidyl choline (aPC) using enzyme linked immunosorbent assay (ELISA) methods. Sera from 30 patients with systemic lupus erythematosus (SLE), but without features of anti-phospholipid syndrome (APS) (SLE/non APS), six with SLE and secondary APS, (SLE/APS) and 11 with primary APS (PAPS) were also evaluated as controls. The resistance of the aPL antibody binding to dissociating agents was evaluated by treating the ELISA wells, after serum incubation with 2 M urea or 0.6 M NaCl for 10 min. An anti-beta2-glycoprotein-I (beta2-GPI) ELISA was used to assess serum reactivity against beta2-GPI, a plasma protein considered as the true antigen of aCL antibodies occurring in APS and SLE patients. The prevalence of aCL, aPS, aPI and aPC antibodies in HIV-1 infection was 36%, 56%, 34% and 43% respectively, which was comparable to that found in SLE/APS and PAPS patients and significantly higher than that observed in SLE/non-APS patients. Anti-beta2-GPI antibodies occurred in 5% of HIV-1 infected vs. 17% in SLE/non-APS (P=0.11), 50% in SLE/APS (P=0.009) and 70% in PAPS patients (P=0.0014). A significant decrease of aPL binding after urea and NaCl treatment was observed in the sera of HIV-1-infected, compared to that of APS patients, indicating that aPL antibodies from HIV-1 infected individuals have low resistance to dissociating agents. In conclusion, aPL antibodies (1) occur in HIV-1 infection; (2) tend to recognize various phospholipids but not beta2-GPI; and (3) are of low resistance to dissociating agents-a finding probably reflecting low antibody avidity. Finally, these, like the autoimmune-type aCL antibodies, tend to recognize the oxidized CL-a finding probably indicating autoantibody generation as a result of neoepitope formation by oxidized PLs. Copyright 1999 Academic Press.


Keywords: JOURNAL ARTICLE Adult Anti-HIV Agents/THERAPEUTIC USE Antibodies, Anticardiolipin/IMMUNOLOGY Antibody Affinity/*IMMUNOLOGY Antibody Specificity/*IMMUNOLOGY Antiphospholipid Syndrome/COMPLICATIONS/*IMMUNOLOGY Cardiolipins/IMMUNOLOGY Comparative Study Female Glycoproteins/*IMMUNOLOGY Hepatitis C/COMPLICATIONS/IMMUNOLOGY Human HIV Infections/DRUG THERAPY/*IMMUNOLOGY Lupus Erythematosus, Systemic/COMPLICATIONS/*IMMUNOLOGY Male Phospholipids/*IMMUNOLOGY Pneumonia, Pneumocystis carinii/COMPLICATIONS/IMMUNOLOGY Reverse Transcriptase Inhibitors/THERAPEUTIC USE Sodium Chloride/IMMUNOLOGY Urea/IMMUNOLOGYKWDjournalarticleadultanti-hivagents/therapeuticuseantibodies,anticardiolipin/immunologyantibodyaffinity/KWDimmunologyantibodyspecificity/KWDimmunologyantiphospholipidsyndrome/complications/KWDimmunologycardiolipins/immunologycomparativestudyfemaleglycoproteins/KWDimmunologyhepatitisc/complications/immunologyhumanhivinfections/drugtherapy/KWDimmunologylupuserythematosus,systemic/complications/KWDimmunologymalephospholipids/KWDimmunologypneumonia,pneumocystiscarinii/complications/immunologyreversetranscriptaseinhibitors/therapeuticusesodiumchloride/immunologyurea/immunology
000530
A0052248

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .